Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Granulocyte colony stimulating factor (GCSF) Clear all
Completed Phase 2Phase 3 Interventional

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

NCT00004255
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Chimeric Therapies
Industry
Eligibility
12 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
15
States / cities
La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

NCT01989325
View directory record Official record
Conditions
Advanced Multiple Myeloma
Interventions
Carfilzomib, proteasome inhibitor; intravenous, Filanesib, KSP(Eg5) inhibitor; intravenous, Dexamethasone, steroid; oral or intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Hot Springs, Arkansas • Los Angeles, California • Santa Rosa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 18, 2026, 2:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors

NCT00511550
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer

NCT00255710
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Collection of Bone Marrow From Donors Treated With or Without Filgrastim

NCT01149096
View directory record Official record
Conditions
Healthy Stem Cell Donor, No Evidence of Disease
Interventions
Bone Marrow Donation, Filgrastim, Laboratory Biomarker Analysis
Procedure · Biological · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
22
States / cities
San Francisco, California • Aurora, Colorado • St. Petersburg, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 18, 2026, 2:48 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005960
View directory record Official record
Conditions
Pain, Prostate Cancer
Interventions
filgrastim, cyclophosphamide, docetaxel, doxorubicin hydrochloride, pain therapy
Biological · Drug · Procedure
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Los Angeles, California • Vero Beach, Florida • Great Neck, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

NCT00134082
View directory record Official record
Conditions
Lymphoma
Interventions
KGEL vaccine, Filgrastim, Rituximab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Withdrawn Phase 4 Interventional

Use Art-assist and Neupogen to Treat Chronic Limb Ischemia

NCT02408991
View directory record Official record
Conditions
Lower Limb Ischemia
Interventions
Neupogen, Art-Assist Device
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

NCT00003042
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

NCT01096368
View directory record Official record
Conditions
Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Cisplatin, Clinical Observation, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Mesna, Vincristine
Radiation · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 21 Years
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

NCT02494921
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel-PNP, Ribociclib, Prednisone, Filgrastim
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

NCT02423915
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, Fludarabine, Cyclophosphamide, Total Body Radiation, Fucosylated Regulatory T Cells, Cord Blood Infusions, Mycophenolate mofetil, Sirolimus, Bone Marrow Aspiration, G-CSF, Non-Fucosylated Regulatory T Cells
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 18, 2026, 2:48 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003899
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, cyclophosphamide, melphalan, paclitaxel, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

NCT00070304
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

NCT00002833
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions
Filgrastim, Cladribine, Cyclosporine, Cytarabine (Ara-C), Fludarabine Phosphate, Idarubicin, Methylprednisolone, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy
Drug · Procedure · Radiation
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

NCT03417284
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

NCT00002838
View directory record Official record
Conditions
Leukemia
Interventions
Filgrastim (G-CSF), Cyclophosphamide, Fludarabine Phosphate, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

NCT01026987
View directory record Official record
Conditions
Stem Cell Transplant Patients
Interventions
G-CSF, AMD3100, Leukapheresis, Stem Cell Infusion
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 18, 2026, 2:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Hemoglobinopathy

NCT00176852
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
Interventions
Busulfan, Fludarabine, ATG, TLI, Busulfan, Cyclophosphamide, ATG, GCSF, Campath, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 18, 2026, 2:48 AM EDT